Conversely, studies conducted in AML revealed that blasts with TP53 mutations are less sensitive to VEN and that inactivation of TP53 or its pro-apoptotic targets (BAX, PMAIP1) confers resistance to VEN [42]. Here, TP53 is linked to acute myeloid leukemia.